Venus Concept (VERO) Stock Price

Venus Concept Price

NASDAQ·CLOSED
0.31
​
Market closed

Revenue has compounded at 15.9% per year over the past 9 years to 64.83 M USD. Venus Concept's net margin stands at -72.5%, up from -106.2% several years earlier. Analysts set a median price target of 1.02 USD, implying 228.5% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus.

Venus Concept stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Venus Concept business model & stock analysis

Venus Concept, Inc. generates revenue through its portfolio of medical aesthetic and hair restoration technologies, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Freeze Plus, Venus Heal, Venus Skin, and Venus Bliss. The company sells these products to clinics and medical practices globally, operating in over 60 countries and 29 direct markets. Its hair restoration division features NeoGraft, an automated system for follicular unit extraction (FUE) procedures. Venus Viva combines NanoFractional Radio Frequency (RF) and SmartScan technology for facial, neck, and body treatments, while Venus Fiore targets vaginal health restoration with three specialized applicators. The company’s revenue streams include direct sales of devices and related practice enhancement services. Products like Venus Legacy and Venus Freeze Plus are marketed for non-invasive aesthetic procedures, while NeoGraft serves the hair restoration segment. Venus Fiore focuses on internal vaginal health, labia tightening, and mons pubis reduction, addressing niche medical needs. All offerings are distributed through the company’s global network, leveraging its presence in 29 direct markets. Venus Concept’s business model centers on selling minimally invasive and non-invasive medical aesthetic technologies to healthcare providers. The company’s product range spans multiple applications, from facial rejuvenation to hair restoration and intimate health. By maintaining a diverse portfolio under its branded products, Venus Concept ensures steady demand across various medical specialties and geographic regions.

Frequently asked questions about Venus Concept

6 analysts currently rate the Venus Concept stock: 0 recommend buying, 3 holding and 3 selling. For 2026, analysts expect Venus Concept to generate revenue of 65.80 M USD and earnings per share of -2.14 USD.

Converted at the current exchange rate, the Venus Concept share trades at 0.28 EUR (0.31 USD).

The Venus Concept share (VERO) is listed on 3 stock exchanges, including: NASDAQ (VERO), Frankfurt (0RR1.F), München (0RR1.MU).

The expected revenue of Venus Concept is 65.80 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Venus Concept is -9.32 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Venus Concept is currently -0.15. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Venus Concept stock.

The price-to-sales ratio (P/S) of Venus Concept is currently 0.02. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Venus Concept stock.

The Eulerpool Quality Score for Venus Concept is 2/10.

The ISIN of Venus Concept is US92332W3034. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Venus Concept is A2PU7A. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Venus Concept is VERO. The ticker symbol is used to trade Venus Concept shares on the stock exchange.

Fair ValueTerminal
0.26 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
222,030.82 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
USD
Initial public offering
Oct 12, 2017
ISIN
US92332W3034
Cusip
92332W105
Sedol
BG0WPM4
Market capitalization
52-Week Range
PEG
—
P/E ratio
P/Ee 2025
-0.04
P/Ee 2026
-0.15
P/S
P/Se
0.02
EV/EBIT
—
P/B Ratio
0.24
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-111.69 %
Last updated Oct 26, 2026, 9:28 AM

Venus Concept Ticker

FRANKFURT · 0RR1.FMUNICH · 0RR1.MUNASDAQ · VERO

All fundamentals and in-depth analysis of Venus Concept

Our stock analysis for Venus Concept stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Venus Concept. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.